Cite
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
MLA
Dickhoff, Chris, et al. “Ipilimumab plus Nivolumab and Chemoradiotherapy Followed by Surgery in Patients with Resectable and Borderline Resectable T3-4N0-1 Non-Small Cell Lung Cancer: The INCREASE Trial.” BMC Cancer, vol. 20, Aug. 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-020-07263-9.
APA
Dickhoff, C., Senan, S., Schneiders, F. L., Veltman, J., Hashemi, S., Daniels, J. M. A., Fransen, M., Heineman, D. J., Radonic, T., van de Ven, P. M., Bartelink, I. H., Meijboom, L. J., Garcia-Vallejo, J. J., Oprea-Lager, D. E., de Gruijl, T. D., & Bahce, I. (2020). Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. BMC Cancer, 20, 1–10. https://doi.org/10.1186/s12885-020-07263-9
Chicago
Dickhoff, Chris, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, et al. 2020. “Ipilimumab plus Nivolumab and Chemoradiotherapy Followed by Surgery in Patients with Resectable and Borderline Resectable T3-4N0-1 Non-Small Cell Lung Cancer: The INCREASE Trial.” BMC Cancer 20 (August): 1–10. doi:10.1186/s12885-020-07263-9.